IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Inc.

In a report released yesterday, Michael Ryskin from Bank of America Securities maintained a Hold rating on Idexx Laboratories, with a price target ...

Bank of America Securities Reaffirms Their Hold Rating on Idexx Laboratories (IDXX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on aTyr Pharma (ATYR) and Idexx Laboratories (IDXX). ...

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (ATYR) and Idexx Laboratories (IDXX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE) and Idexx Laboratories (IDXX). Pfizer (PFE) Jefferie...

Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Idexx Laboratories (IDXX)

For the last few weeks, we’ve been talking about the risks piling up in the market. Like back in January, when we called valuations pornographic. T...

Market Cap	$50.50B	P/E Ratio	40.19
52W High	$769.98	52W Low	$356.14
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	7.2%	52W Position	55.2%
Overall Score	40	Value Score	30
Quality Score	65	Technical Score	27

EPS Current Est	$14.55	EPS Next Est	$16.36
EPS Growth Est	+12.4%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IDXX	$584.75	-1.20%	447.64K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IDXX	$584.75	-1.2%	447.64K
3
4
5
6

IDXX

IDXX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get IDEXX Laboratories Inc. Data in Excel

Get IDEXX Laboratories Inc. Data in Excel